MedTrace Logo

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

NCT00290550 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-07-27

No results posted yet for this study

Summary

This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

MK0457

IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-05-31
Completion
2007-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290550 on ClinicalTrials.gov